Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca reported first quarter 2026 results highlighting major investment in its RAS-targeting pipeline. The company ended March 31, 2026 with $408.5 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2028.
Total operating expenses rose to $187.9 million, driven by $150.0 million of in-process R&D expense to obtain worldwide rights to ERAS-0015, alongside $27.3 million in R&D and $10.6 million in G&A. Net loss widened to $183.4 million, or $(0.60) per share.
Strategically, Erasca advanced ERAS-0015 and ERAS-4001, signed clinical trial collaborations with Merck and Tango Therapeutics, secured a U.S. composition of matter patent for ERAS-4001 through June 2043, expanded ERAS-0015 licensing territory, and completed an upsized public offering raising approximately $258.8 million in gross proceeds.
Erasca, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only webcast at 11:30 a.m. Pacific Time on June 26, 2026. Holders of 310,965,971 shares of common stock as of April 27, 2026 may vote.
Stockholders will elect three Class II directors (Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.) and vote on ratifying KPMG LLP as independent registered public accounting firm for 2026. The proxy also details board governance practices and 2025 executive pay, including CEO Jonathan Lim’s total compensation of $4.3 million and sizable stock option grants.
Erasca, Inc. reported positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Early results come from the AURORAS-1 trial in the United States and the JYP0015M101 trial in China.
The studies enroll patients with colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma, tumor types where KRAS mutations affect an estimated 74,000, 55,000 and 50,000 patients per year in the United States. Erasca has already started ERAS-0015 monotherapy expansion and combination dose escalation cohorts in the United States earlier than its prior guidance.
The company emphasizes that the data are preliminary, include information from a third-party licensor and involve cross-study comparisons that are inherently limited. It highlights multiple development and regulatory risks, including the possibility that future, more complete trial results may differ from current observations.
Erasca, Inc. updated the expected timing for initial Phase 1 monotherapy data from its pan-RAS molecular glue ERAS-0015, now guiding that data from the AURORAS-1 and JYP0015M101 trials will be available no later than mid-May 2026, compared with its prior expectation of the first half of 2026.
AURORAS-1 is evaluating ERAS-0015 in patients with RAS-mutant solid tumors, while licensor Guangzhou Joyo Pharmatech Co., Ltd. is running JYP0015M101 in China in patients with advanced solid tumors harboring specific RAS mutations. The company also highlights typical forward-looking statement risks and directs readers to its risk factor disclosures.
Erasca Foundation reported proposed sales of Common stock in Form 144/A. The filing lists sales dated 01/15/2026, 02/17/2026, and 03/16/2026 with amounts $68,573.87, $99,245.03, and $116,855.46 respectively. The entries are recorded under Erasca Foundation's address in San Diego and identify the securities as Common stock.
Erasca Foundation reported sale transactions of Common stock via Form 144 and lists multiple recent dispositions by the foundation. The filing itemizes dated transfers on 01/15/2026, 02/17/2026, and 03/16/2026 with corresponding amounts shown in the excerpt.
Erasca, Inc. Chief Legal Officer Ebun Garner exercised stock options and sold shares in a planned transaction. On April 1, 2026, Garner exercised options to acquire 80,000 shares of common stock at $1.70 per share, converting a derivative position into common stock.
That same day, Garner sold 80,000 shares of common stock at a weighted-average price of $16.40 per share in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2024. Following these transactions, Garner directly held 25,076 shares of Erasca common stock.
Erasca, Inc. filed a Form 144 reporting a proposed sale of 80,000 shares of Common Stock associated with a stock option, planned for 04/01/2026 and to be settled for cash. The filing shows an aggregate value of $1,312,354.68 and lists 310,799,547 shares outstanding as of 04/01/2026 as a context figure. The filer also reported a prior sale of 120,000 shares on 01/07/2026 for $670,809.15.